Prevalence of Nonalcoholic Fatty Liver Disease and Economy

Zhu, Jinzhou; Dai, Yihu; Wang, Yuming; Zhou, Qianxiang; Yu, Chaohui; Li, Youming

doi:10.1007/s10620-015-3728-3

Cited by 108 publications

(73 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were three differences between two studies. Firstly, the prevalence of NAFLD in our study was 20.5% that was close to the average level based on a number of population-based surveys [15], while the study of Li et al reported a prevalence of 37.0%. We believe our study could present a current situation of NALFD in western China.…”

Section: Discussionsupporting

confidence: 83%

“…NAFLD has become an emerging public health concern, given its remarkable growth in the worldwide over the recent decades [15]. Specifically, due to the westerni- zation of lifestyle and the aging population, the prevalence of NAFLD, closely related with metabolic disorders such as central obesity, hypertriglyceridemia and insulin resistance, has witnessed a rapid increase in Asia [16,17].…”

Section: Discussionmentioning

confidence: 99%

“…However, it has some limitations. To begin with, the participants that afforded the expense of the annual physical checkup in the urban area tend to have higher socioeconomic status, which might lead to a higher prevalence of NAFLD [15] and a selection bias. Meanwhile, the expenditure of the indexes was evaluated based on the price of Beijing Medical Service.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Validation of simple indexes for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study

Zhu

Zhang

et al. 2018

Endocr J

View full text Add to dashboard Cite

Abstract. Various noninvasive algorithms have been developed for predicting the presence of nonalcoholic fatty liver disease (NAFLD). The evaluation of the indexes' diagnostic performance has been reported in Europe and Asia over the past decade; however, external validation of them in China is rare. This study was aimed to evaluate various indexes for NAFLD in western China. It was a retrospective cross-sectional study, using data from a large-scale health check-up project at Sichuan provincial hospital. Receiver operating characteristic (ROC) curves of eight indexes, including the fatty liver index (FLI), the hepatic steatosis index, lipid accumulation product and etc., were developed to predict ultrasonographic NAFLD. There were 13,122 subjects in this study (2,692 NAFLD patients and 10,430 non-NAFLD participants). The area under ROC curve of FLI for predicting NAFLD was 0.880 (95% confidence interval, 0.874-0.886), which was significantly higher than other seven indexes. Accuracy, sensitivity and specificity of FLI for NAFLD were good (cut-off value = 30, 0.782, 0.832, 0.770 and cut-off value = 60, 0.838, 0.443, 0.940, respectively). Furthermore, FLI also presented advantages in expenditure and accessibility, compared with other indexes. It supports FLI as an easily accessible index for physicians and a reliable predictor for NAFLD screening in western China.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Validation of simple indexes for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study

Zhu

Zhang

et al. 2018

Endocr J

View full text Add to dashboard Cite

show abstract

“…Nonalcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease in developed countries and its increased prevalence parallels the rise in obesity, type 2 diabetes and metabolic syndrome in recent decades (Tuyama & Chang 2012, Yki-Jarvinen 2016. NAFLD encompasses hepatic steatosis driven by factors other than excessive alcohol consumption and is estimated to affect 25% of the global population (Zhu et al 2015). While NAFLD most commonly refers to fatty liver resulting from overnutrition and consumption of a western diet, NAFLD may also be induced by endocrine disorders, viral infections or side effects of pharmacological therapies.…”

Section: Introductionmentioning

confidence: 99%

Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones

Geisler

Renquist

2017

Journal of Endocrinology

155

View full text Add to dashboard Cite

Fatty liver can be diet, endocrine, drug, virus or genetically induced. Independent of cause, hepatic lipid accumulation promotes systemic metabolic dysfunction. By acting as peroxisome proliferator-activated receptor (PPAR) ligands, hepatic non-esterified fatty acids upregulate expression of gluconeogenic, beta-oxidative, lipogenic and ketogenic genes, promoting hyperglycemia, hyperlipidemia and ketosis. The typical hormonal environment in fatty liver disease consists of hyperinsulinemia, hyperglucagonemia, hypercortisolemia, growth hormone deficiency and elevated sympathetic tone. These endocrine and metabolic changes further encourage hepatic steatosis by regulating adipose tissue lipolysis, liver lipid uptake, de novo lipogenesis (DNL), beta-oxidation, ketogenesis and lipid export. Hepatic lipid accumulation may be induced by 4 separate mechanisms: (1) increased hepatic uptake of circulating fatty acids, (2) increased hepatic de novo fatty acid synthesis, (3) decreased hepatic beta-oxidation and (4) decreased hepatic lipid export. This review will discuss the hormonal regulation of each mechanism comparing multiple physiological models of hepatic lipid accumulation. Nonalcoholic fatty liver disease (NAFLD) is typified by increased hepatic lipid uptake, synthesis, oxidation and export. Chronic hepatic lipid signaling through PPARgamma results in gene expression changes that allow concurrent activity of DNL and beta-oxidation. The importance of hepatic steatosis in driving systemic metabolic dysfunction is highlighted by the common endocrine and metabolic disturbances across many conditions that result in fatty liver. Understanding the mechanisms underlying the metabolic dysfunction that develops as a consequence of hepatic lipid accumulation is critical to identifying points of intervention in this increasingly prevalent disease state.

show abstract

“…The prevalence of obesity-related metabolic disorders is mounting to epidemic proportions in the world (1)(2)(3). Obesity, insulin resistance (IR), dyslipidemia, hyperglycemia, and hypertension are frequently coincident in one individual, in a disorder defined as metabolic syndrome (MetS) (4).…”

Section: Introductionmentioning

confidence: 99%

Aumento del nivel de betatrofina en suero en sujetos con síndrome metabólico: estudio de casos y controles

Zhu¹,

Li²,

Dai³

et al. 2016

Nutr Hosp

Self Cite

View full text Add to dashboard Cite

ResumenIntroducción: la betatrofina es una novedosa adipoquina que provoca la proliferación de células β pancreáticas e interviene en el metabolismo de los lípidos. Objetivos: el propósito de este estudio es evaluar el papel de la betatrofina en el síndrome metabólico. Método: se llevó a cabo un estudio hospitalario de casos y controles según sexo y edad. El nivel de betatrofina en suero fue evaluado mediante ensayo por inmunoabsorción ligado a enzimas. Se midieron las concentraciones en suero de 12 adipoquinas para evaluar las asociaciones con la betatrofina usando los kits comerciales Adipokine Magnetic Bead Panel. Los análisis estadísticos incluyeron correlación bivariada, análisis de curva ROC y análisis de regresión lineal multivariable. Resultados: el nivel de betatrofina en suero fue más elevado en pacientes con síndrome metabólico (997,36 ± 475,92 pg/ml, p = 0,001) que en los controles (735,35 ± 526,51 pg/ml). Frente al tercil más bajo, el tercil más alto del nivel de betatrofina mostró una asociación con mayor riesgo de síndrome metabólico (odds ratio ajustado = 3,521, intervalo de confianza [IC] 95% [1,413], p = 0,023). Se desarrolló la curva ROC de betatrofina para pronosticar la presencia de síndrome metabólico (área bajo la curva ROC = 0,682 [95% IC, 0,597-0,767], p < 0,001). Además, la betatrofina mostró correlación con distintos parámetros, como edad (r = 0,286, p < 0,001), índice de masa corporal (r = 0,160, p = 0,046), índice cintura-cadera (r = 0,241, p = 0,002), lipoproteína de alta densidad (r = -0,167, p = 0,037), lipoproteína de baja densidad (r = -0,195, p = 0,015), glucosa plasmática en ayunas (r = 0,266, p = 0,001), hemoglobina A1C (r = 0,314, p < 0,001), índice de resistencia a la insulina mediante HOMA (r = 0,272, p = 0,001) y diversas adipoquinas, entre ellas resistina (r = 0,571, p < 0,001), interleucina-8 (r = 0,435, p < 0,001), factor de necrosis tumoral alfa (r = 0,295, p = 0,011) y lipocalina-2 (r = 0,346, p = 0,003). Conclusiones: este estudio demuestra que la betatrofina en suero desempeña una importante labor en el síndrome metabólico, implicando la regulación del metabolismo de la glucosa y los lípidos y la inflamación. AbstractBackground: Betatrophin is a novel adipokine that provokes pancreatic β-cell proliferation and is involved in lipid metabolism. Aims: This study aims to evaluate the role of serum betatrophin in metabolic syndrome (MetS). Methods: A hospital-based, age-/gender-matched case control study was conducted. The serum betatrophin level was evaluated by enzymelinked immunosorbent assay. Serum concentrations of 12 adipokines were measured to assess their associations with serum betatrophin, using commercial Adipokine Magnetic Bead Panel kits. Statistical analyses included bivariate correlation, receiver operating characteristic (ROC) curve, and multivariate stepwise linear regression. Conclusions: This study supports that serum betatrophin plays an important role in MetS, involving the regulations of glucose and lipid metabolism and inflammation.

show abstract

Prevalence of Nonalcoholic Fatty Liver Disease and Economy

Abstract: This study suggested that countries with higher economic status tend to present a higher prevalence of NAFLD. It is believed to provide a distinctive epidemiologic perspective to global situation of NAFLD.

Cited by 108 publications

References 43 publications

Validation of simple indexes for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study

Validation of simple indexes for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study

Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones

Aumento del nivel de betatrofina en suero en sujetos con síndrome metabólico: estudio de casos y controles

Contact Info

Product

Resources

About